Gregory Connor, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $364,410 of the $444,477 with a category attached, or 82.0%. SK Life Science, Inc. accounts for 99.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $128,288 and has fallen 77.5% since, to $28,823 in 2025. Among neurology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 586 payments — averaging $758.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$440K
- UCB, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$313
- Biohaven Pharmaceuticals, Inc.$125
- Amgen$125
- Biogen$124
- plus $347 from 3 others
Across 3 payments — averaging $789.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$2K
- UCB, Inc.$580
What the payments were for
- Consulting fees$30,0557%
- Speaking & faculty fees$364,41082%
- Travel & lodging$36,9818%
- Food & beverage$12,8313%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 567 | $440,358 |
| UCB, Inc. | 9 | $3,085 |
| Teva Pharmaceuticals USA, Inc. | 4 | $313 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 1 | $125 |
| Biogen | 1 | $124 |
| EMD Serono, Inc. | 1 | $124 |
| Neurelis, Inc. | 1 | $114 |
| Pfizer | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$392,431
- Cenobamate$35,394
- Briviact$3,000
- NURTEC ODT$125
- AIMOVIG$125
- Mavenclad$124
- AJOVY$123
- VALTOCO$114
- ZAVZPRET$109
How this compares
$444,477 in reported general payments places this provider in the 95th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 780 | $1,108,753 |
| BriviactBrivaracetam | 414 | $639,569 |
| Vigabatrin | 13 | $241,923 |
| EpidiolexCannabidiol (Cbd) | 38 | $157,300 |
| Lacosamide | 1,080 | $119,275 |
| FycompaPerampanel | 77 | $90,982 |
| ValtocoDiazepam | 26 | $54,712 |
| ZonegranZonisamide | 12 | $46,799 |
| Levetiracetam | 988 | $30,959 |
| Tetrabenazine | 13 | $21,241 |
| NayzilamMidazolam | 15 | $20,041 |
| Topiramate | 1,461 | $18,784 |
| Emgality PenGalcanezumab-Gnlm | 23 | $17,646 |
| Nurtec OdtRimegepant Sulfate | 14 | $16,005 |
| Rufinamide | 15 | $15,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $440,358 | $1,108,753780 claims |
| UCB, Inc.Briviact, Nayzilam | $3,085 | $659,610429 claims |
| Neurelis, Inc.Valtoco | $114 | $54,71226 claims |
| PfizerNurtec Odt | $109 | $16,00514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 neurology providers in Oklahoma.
Other neurology in Tulsa
- Jaclyn DuvallTulsa$1.4M
- Tania ReynaTulsa$353K
- Christopher GlissonTulsa$125K
- Alok PasrichaTulsa$81K
- Aimee BorazanciTulsa$75K
- Randall WebbTulsa$31K
- Todd DunawayTulsa$26K
- Jeremy SalasTulsa$20K
- Jorge GonzalezTulsa$19K
- Kenny SusantoTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.